LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

Home・Elenco Azioni・Cogent Biosciences Inc

Cogent Biosciences Inc

Aperta

36.84 -3.38

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

36.33

Massimo

38.97

Metriche Chiave
By Trading Economics
Entrata	-7.4M -81M
EPS	-0.5
Dipendenti	205
EBITDA	-6.8M -79M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+39.74% upside

Dividendi
By Dow Jones
Utili prossimi	5 mag 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	3.4B 5.6B
Apertura precedente	40.22
Chiusura precedente	36.84

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

4.88 / 5.87 Supporto e resistenza

Cogent Biosciences Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

22 feb 2026, 23:55 UTC

Discorsi di Mercato

Gold and Silver Rise Amid Renewed Trade Tensions -- Market Talk

22 feb 2026, 23:53 UTC

Discorsi di Mercato

Japan Activity Data Set to Show Strength, Backed by Fiscal Spending -- Market Talk

22 feb 2026, 23:53 UTC

Discorsi di Mercato

Key China Rates Likely to Be Held Steady for Now -- Market Talk

22 feb 2026, 23:51 UTC

Discorsi di Mercato

Bank of Korea Set to Hold Fire as Inflation Steadies, Risks Linger -- Market Talk

22 feb 2026, 23:35 UTC

Discorsi di Mercato

Oil Falls Amid Prospect That U.S. Strike on Iran Might Be Limited -- Market Talk

22 feb 2026, 23:21 UTC

Utili

Nickel Industries 2025 Adjusted Ebitda US$283.0 Million

22 feb 2026, 23:20 UTC

Utili

Nickel Industries 2025 Operating Profit US$126.4 Million

22 feb 2026, 23:19 UTC

Utili

Nickel Industries 2025 Revenue US$1.65 Billion, Down 5.5% On-Year

22 feb 2026, 23:19 UTC

Utili

Correct: Nickel Industries 2025 Net Loss US$57.1 Million, Down 66% On-Year

22 feb 2026, 23:18 UTC

Utili

Nickel Industries Won't Pay a Final Dividend

22 feb 2026, 23:16 UTC

Utili

Nickel Industries 2025 Net Loss A$57.1 Million, Down 66% On-Year

22 feb 2026, 21:35 UTC

Utili

Ampol Expects to Start Commissioning of Ultra Low Sulfur Fuels Project in 2Q

22 feb 2026, 21:34 UTC

Utili

Ampol Says F&I Australia, International Have Begun 2026 Strongly

22 feb 2026, 21:34 UTC

Utili

Ampol Expects Stage 1 of Fuel Security Services Payment Review Finalized in 1Q

22 feb 2026, 21:33 UTC

Utili

Ampol Says Lytton Refiner Margin Was US$8.13/bbl in January

22 feb 2026, 21:33 UTC

Utili

Ampol Recognizes A$89.9 Million Impairment in Carrying Value of Investment in Seaoil

22 feb 2026, 21:28 UTC

Utili

Ampol Final Dividend A$0.60/Share

22 feb 2026, 21:28 UTC

Utili

Ampol FY Revenue A$31.37 Billion, Down 10%

22 feb 2026, 21:28 UTC

Utili

Ampol FY Replacement-Cost Net Profit A$429.2 Million, Up 83%

22 feb 2026, 21:28 UTC

Utili

Ampol FY Historical-Cost Net Profit A$82.4 Million, Down 33%

21 feb 2026, 14:31 UTC

Acquisizioni, Fusioni, Takeovers

Bridgewater Associates' 4Q Buying and Selling -- Barrons.com

21 feb 2026, 05:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

20 feb 2026, 23:12 UTC

Acquisizioni, Fusioni, Takeovers

FERC Authorizes TXNM Energy Acquisition by Blackstone Infrastructure

20 feb 2026, 22:12 UTC

Utili

Equinox Gold: Announces Filing of 2025 Audited Fincl Statements

20 feb 2026, 21:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

20 feb 2026, 21:50 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

20 feb 2026, 21:23 UTC

Utili

These Stocks Are Today's Movers: Grail, Corning, Comfort Systems USA, Opendoor, Akamai, Chemours, and More -- Barrons.com

20 feb 2026, 21:20 UTC

Discorsi di Mercato

Century Aluminum Backs Trump's Tariffs After SCOTUS Ruling -- Market Talk

20 feb 2026, 21:01 UTC

Acquisizioni, Fusioni, Takeovers

Want to Win the Warner Bros. Discovery Takeover Battle? 'Walk Away Now.' -- Barrons.com

20 feb 2026, 20:38 UTC

Discorsi di Mercato

U.S. Natural Gas Gains Ahead of Chilly Weekend -- Market Talk

Confronto tra pari

Modifica del prezzo

Cogent Biosciences Inc Previsione

Obiettivo di Prezzo

By TipRanks

39.74% in crescita

Previsioni per 12 mesi

Media 52.18 USD 39.74%

Alto 67 USD

Basso 35 USD

Basato su 12 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Cogent Biosciences Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

12 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 12 che hanno fornito valutazioni azionarie a Cogent Biosciences Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

4.88 / 5.87Supporto e resistenza

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.